2023-05-24 11:09:47
A spectacular advance. It is in these terms that the specialists describe the excellent results of an innovative treatment once morest cancer, developed by Professor Cyril Cohen, head of the laboratory of immunology and immunotherapy at Bar Ilan University, in collaboration with Pr Polina Stepansky from Hadassah Hospital.
This treatment, used once morest myeloma cancer, uses the genetic modification of cells of the immune system of patients, a revolutionary idea born in the 1980s in the Department of Immunology of Professor Zelig Ashchar, at the Weizmann Institute of Science.
“It is administered in one go, following taking and modifying the patient’s cells in the laboratory, thanks to a virus that we have developed. Reinjected, the patient’s white blood cells are then able to fight once morest cancer cells”, a explained Professor Cohen on i24NEWS. “Myeloma cancer, incurable to date, represents approximately 1% of cancers and 10% of blood cancers. The results we have obtained therefore constitute immense hope.”
Each year, between 400 and 500 new patients are diagnosed with the disease in Israel, most of them over the age of 70. The origin of the disease is in type B white blood cells. Myeloma begins when healthy plasma cells, which are made up of blood cells, change and grow uncontrollably.
As a result, the disease affects bone marrow, bones, kidneys and the immune system. More than a decade ago, the treatment of multiple myeloma underwent a significant change with the development of new biological drugs, but a treatment that might lead to a cure for the disease had never been developed.
The clinical trials of this new treatment, which began in February 2021, are in phase two of the three necessary for it to be validated by the health authorities and marketed. Eventually, the treatment might also be extended to other types of cancer.
1684927655
#Israel #Dramatic #Results #Myeloma #Cancer #Treatment
